๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Nasopharyngeal Carcinoma (NPC)
Clinical trial register · China

Nasopharyngeal Carcinoma (NPC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 16 Nanning 7 Shanghai 4 Zhuhai 3 Changsha 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou16 Nanning7 Shanghai4 Zhuhai3 Changsha3
All 29 locations
Target enrolment
to

Nasopharyngeal Carcinoma (NPC) trials in China

38 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
NCT07756190Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
28
Guangzhou
2026-09-01
Not yet open
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
NCT07303283Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
Kai Hu
Phase 2
140
Nanning
2026-09-01
Not yet open
Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma
NCT07789158Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 2
269
Shanghai
2026-09-01
Not yet open
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
NCT07797881Nasopharyngeal Carcinoma (NPC)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
60
Guangzhou
2026-09
Not yet open
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
NCT07818486Nasopharyngeal Carcinoma (NPC), Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
30
Chongqing, Guangzhou
2026-09
Not yet open
Impacted Tooth Management and Osteoradionecrosis Risk in NPC
NCT07764887Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw
First Affiliated Hospital of Guangxi Medical University
Not applicable
536
Baise City, Beihai, Guigang, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2026-08-30
Recruiting
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
NCT07819656Nasopharyngeal Carcinoma (NPC), Myelosuppression
Nanfang Hospital, Southern Medical University
Observational
1,782
Guangzhou
2026-08-26
Not yet open
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07064902Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 2
48
Xiamen, Guangzhou, Guilin
2026-08-01
Recruiting
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
NCT07781358Nasopharyngeal Carcinoma (NPC)
Hongmeng Yu
Phase 2
25
Shanghai
2026-08-01
Recruiting
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
NCT07762976Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 2
148
Shanghai
2026-08
Not yet open
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
NCT07567742Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 2
130
Guangzhou
2026-05-06
Recruiting
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
NCT07590024Nasopharyngeal Carcinoma (NPC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
651
Beijing
2026-05-01
Recruiting
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
NCT07459296Nasopharyngeal Carcinoma (NPC)
First Affiliated Hospital of Guangxi Medical University
Phase 3
266
Nanning
2026-03-05
Recruiting
Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
NCT06796270Nasopharyngeal Carcinoma (NPC)
The Second Affiliated Hospital of Hainan Medical University
Not applicable
24
Haikou
2026-02-20
Not yet open
Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07388758Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-02
Recruiting
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
NCT07618078Nasopharyngeal Carcinoma (NPC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
900
Beijing
2026-01-01
Recruiting
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
NCT07340515Nasopharyngeal Carcinoma (NPC)
Man Hu
Phase 3
300
Jinan
2025-12-15
Recruiting
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen
Phase 3
456
Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong
2025-11-18
Recruiting
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
NCT07101744Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
41
Guangdong
2025-10-17
Recruiting
Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
NCT07277764Nasopharyngeal Carcinoma (NPC), Recurrent Nasopharyngeal Neoplasms
Jiangxi Provincial Cancer Hospital
Phase 2
23
Nanchang
2025-10-10
Recruiting
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 3
462
Shanghai, Hangzhou, Chengdu, Chongqing
2025-09-01
Recruiting
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT07137052Nasopharyngeal Carcinoma (NPC), PET / CT
The First Affiliated Hospital of Xiamen University
Observational
732
Xiamen
2025-08-30
Recruiting
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
NCT07188584Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen
Phase 3
166
Zhuhai
2025-08-20
Not yet open
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
NCT06900218Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
664
Guangzhou
2025-05-01
Recruiting
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
NCT06839066Nasopharyngeal Carcinoma (NPC)
Shanghai Henlius Biotech
Phase 2
70
Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2025-04-02
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
NCT06870435Nasopharyngeal Carcinoma (NPC), Screening, Epstein Barr Virus
Ming-Yuan Chen
Not applicable
68,649
Zhuhai
2025-01-24
By invitation
Prognostic Value of TIL in Nasopharyngeal Carcinoma
NCT06763640Nasopharyngeal Carcinoma (NPC)
Jiangxi Provincial Cancer Hospital
Observational
216
Nanchang
2025-01-01
Recruiting
Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
NCT07085988Nasopharyngeal Carcinoma (NPC)
Jiangxi Provincial Cancer Hospital
Phase 2
109
Nanchang
2025-01-01
Active, closed
Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: cfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection
NCT06763289Nasopharyngeal Carcinoma (NPC)
First Affiliated Hospital, Sun Yat-Sen University
Observational
700
Guangzhou
2024-12-25
Recruiting
"Xijiang Project" Screening Cohort for NPC
NCT06787456Nasopharyngeal Carcinoma (NPC), Screening
Ming-Yuan Chen
Observational
1,000,000
Zhuhai
2024-11-14
Not yet open
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
NCT06680115Nasopharyngeal Carcinoma (NPC)
First Affiliated Hospital of Guangxi Medical University
Phase 2
150
Nanning
2024-11
Recruiting
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
NCT06611150Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 1
24
Guangzhou
2024-08-02
Active, closed
Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.
NCT07011329Nasopharyngeal Carcinoma (NPC)
Hubei Cancer Hospital
Observational
60
Wuhan
2023-04-01
Recruiting
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
NCT07327216Nasopharyngeal Carcinoma (NPC)
Affiliated Hospital of Guangdong Medical University
Phase 3
180
Zhanjiang
2022-08-15
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/nasopharyngeal-carcinoma-npc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies listing the condition Nasopharyngeal Carcinoma (NPC).

How many Nasopharyngeal Carcinoma (NPC) trials are recruiting in China?

21 of the 38 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 13 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nasopharyngeal Carcinoma (NPC)), 38 studies
PhaseStudiesRecruitingShare
Phase 214636.8%
Phase 311828.9%
Observational7418.4%
Not applicable4210.5%
Phase 1112.6%
Phase 1/2102.6%

Most active sponsors

Lead sponsors with the most studies (Nasopharyngeal Carcinoma (NPC))
Lead sponsorStudiesRecruiting
Sun Yat-sen University93
Ming-Yuan Chen44
First Affiliated Hospital of Guangxi Medical University31
Fudan University32
Jiangxi Provincial Cancer Hospital32
Sichuan Baili Pharmaceutical Co., Ltd.30
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Affiliated Hospital of Guangdong Medical University11
First Affiliated Hospital, Sun Yat-Sen University10
Guangzhou Concord Cancer Center10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.